Prime Insights

    Reports




Dec. 23, 2015 | Prime Therapeutics

REPORT: Defining parallels

As the Health Insurance Marketplace (HIM) matures into its second year, we’ve discovered a number of interesting parallels — and a few significant differences — in the way public exchange members use medicines and accumulate drug spend.

Report summary | Full report




defining dynamics

Aug. 15, 2015 | Prime Therapeutics

REPORT: 2014 prescription drug cost report — Defining dynamics

Prime Therapeutics (Prime) is pleased to announce our 2014 Report on prescription drug costs. This year, our definition of “drug trend” has evolved to reflect the change in net prescription costs. These costs offer the clearest picture of where costs start and how they compare.

Report summary | Full report




defining variance

June 1, 2015 | Prime Therapeutics

REPORT: Defining variance

Our new white paper, Defining variance, dives deeper into Health Insurance Marketplace data. In it, we explore differences in demographics, use and spend within the five different levels of coverage — identified as “metallic levels.” This analysis revealed more detailed insights and distinctions — and also a few surprises.

Report summary | Full report




Defining evolution

April 3, 2015 | Prime Therapeutics

REPORT: 2014 private exchange report — Defining evolution

Last year, Prime served more than 1.4 million public exchange members. Using data from the first full year of the public exchanges, Prime identified drug usage and cost trends. This data gives us perspective on what the future holds for these members. It also gives us insight on what that might mean for Prime in this market.

Report summary | Full report




The economic viability of a U.S. biosimilars industry

Feb. 24, 2015 | Prime Therapeutics

REPORT: The economic viability of a U.S. biosimilars industry

A new report sponsored by Prime Therapeutics and authored by health economist Alex Brill suggests the market for biosimilars may not be as robust as many hope it will be. Unlike generic drugs, which significantly impacted the traditional pharmacy market with their cost savings, biosimilars face a number of hurdles.

Report summary | Full report




Enabling better outcomes and lower costs through integration

Aug. 6, 2014 | Prime Therapeutics

REPORT: Enabling better outcomes and lower costs through integration

The report draws on a study sponsored by the Blue Cross and Blue Shield Association (BCBSA) that found positive outcomes and medical cost savings when pharmacy benefits are carved in with the medical. The BCBSA study findings are presented alongside data demonstrating Prime’s notable success in achieving the industry’s lowest net ingredient costs.

Report summary | Full report




Looking back, moving foward, report on 2013 drug costs

June 17, 2014 | Prime Therapeutics

REPORT: Prescription drug cost report — Looking back, moving forward

Prime Therapeutics is pleased to introduce our yearly look back at commercial pharmacy costs and spending trends from the previous year. We’ve renamed our annual trend publication to reflect the inclusion of net ingredient costs. Ingredient cost offers the clearest picture of where costs start and how they compare.

Report summary | Full report